PHASE
Beyond's analysis on PHASE
- — Grundig unveils a new premium appliance lineup at IFA 2026, marking the start of a deeper strategic partnership phase
- — Tezspire’s positive Phase 3 eosinophilic esophagitis data open a new growth avenue for the asthma biologic
- — Astellas initiates Phase 3 trial of ASP2138 for CLDN18.2-positive gastric cancer, advancing its oncology pipeline
- — Brii Biosciences shares interim results highlighting HBV cure progress and vaccine advancement backed by a solid cash position
- — Charbone's electrolyzer delivery to Sorel-Tracy advances its Phase 1B green hydrogen project, moving the company closer to commercial production
- — Cyprus is technically ready to join Schengen, but political hurdles remain as EU states weigh the divided island’s reality
- — Atrium Therapeutics advances its cardiovascular pipeline with IND clearance for ATR 1072 and milestone payment from Bristol Myers Squibb collaboration
- — Oculis secures Privosegtor asset from Accure Therapeutics, strengthening its neuro-ophthalmology pipeline and market positioning
- — The nuclear trade is advancing into Phase 2, with ETFs offering full-chain exposure from uranium mining to reactor restarts
- — Aduro and ECOCE complete Phase 1 raw‑material mapping for Mexico’s 1.5 Mt/yr flexible plastic waste and launch hydrothermal carbonization testing
- — Mesoblast hits 300‑patient enrollment target in its pivotal Phase 3 trial for chronic low back pain, advancing the therapy toward possible regulatory approval
Recent news mentioning PHASE
- — Which Solar Stock Has Dominated in 2026: SolarEdge, Enphase Energy, or First Solar?
- — USA: US-Midterms gehen in die heiße Phase: Schadet Trump seiner Partei bei den Zwischenwahlen?
- — Clover Announces Positive Phase 2 Clinical Data for RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates in Older Adults
- — Grundig stellt auf der IFA 2026 neue Produktpalette vor und läutet damit eine neue Phase der strategischen Partnerschaft ein
- — Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study
- — Grundig Unveils New Product Lineup at IFA 2026, Marking a New Phase in Strategic Partnership
- — Podcast: Tenzing eyes “functional” benefits as next phase in UK energy-drinks push
- — ERS 2026 | Mabwell Presents Phase Ib/IIa Clinical Results of Anti-ST2 Monoclonal Antibody 9MW1911 in COPD Patients
- — Tyra Biosciences to Host Conference Call on Initial Results of Oral Dabogratinib from the SURF302 Phase 2 Study for IR NMIBC on September 9, 2026
- — Argo Biopharma to Present Positive Phase II Updated Results of siRNA Therapeutic BW-20805 for HAE at Bradykinin Symposium 2026
- — NVIDIA (NVDA)’s Hugging Face Deal Tests the Next Phase of its AI Strategy
- — Transamerica Strengthens Retirement Distribution Leadership for Next Phase of Growth